Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
REGN - Regeneron Pharmaceuticals, Inc.
Market Cap 80.32B P/E 19.87 EPS this Y 2.90% Ern Qtrly Grth 47.90%
Income 4.32B Forward P/E 17.49 EPS next Y 7.90% 50D Avg Chg -1.00%
Sales 13.49B PEG 2.21 EPS past 5Y 13.62% 200D Avg Chg -3.00%
Dividend N/A Price/Book 3.34 EPS next 5Y 10.50% 52W High Chg -13.00%
Recommedations 2.10 Quick Ratio 4.43 Shares Outstanding 108.42M 52W Low Chg 28.00%
Insider Own 1.53% ROA 7.62% Shares Float 103.45M Beta 0.12
Inst Own 89.78% ROE 16.55% Shares Shorted/Prior 1.98M/2.11M Price 732.12
Gross Margin 53.27% Profit Margin 32.04% Avg. Volume 638,883 Target Price 1,172.08
Oper. Margin 30.83% Earnings Date Oct 31 Volume 606,072 Change -0.94%
Healthcare | Biotechnology | United States
About Regeneron Pharmaceuticals, Inc.

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration with Mammoth Biosciences, Inc. to research, develop and commercialize in vivo CRISPR-based gene editing therapies for multiple tissues and cell types; and with Sonoma Biotherapeutics, Inc. to discover, develop, and commercialize engineered regulatory T cell therapies. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.

Regeneron Pharmaceuticals, Inc. News
12/23/24 Are You a Value Investor? This 1 Stock Could Be the Perfect Pick
12/19/24 Regeneron says study data support big bet on new blood thinners
12/19/24 Regeneron to Advance Two Factor XI Antibodies into a Broad Phase 3 Program Following Positive Phase 2 Proof-of-concept Results
12/18/24 REGN's Eylea HD Shows Non-Inferiority to Eylea in Eye Disease Study
12/18/24 Biotech Stock Roundup: Updates From GILD, REGN, GSK, ANAB Down on Study Data, EWTX Gains
12/17/24 Regeneron Announces Presentation at the 43rd Annual J.P. Morgan Healthcare Conference
12/17/24 Bayer’s Eye Drug Shows Positive Results in Late-Stage Trial
12/17/24 EYLEA HD® (aflibercept) Injection 8 mg Phase 3 Trial Meets Primary Endpoint Showing Improved Vision with Extended Dosing Intervals in Patients with Macular Edema following Retinal Vein Occlusion
12/17/24 Is Regeneron Pharmaceuticals, Inc. (REGN) the Best Weight Loss Stock to Buy Now According to Hedge Funds?
12/16/24 Regeneron Named to Dow Jones Sustainability World Index for Sixth Consecutive Year
12/16/24 Roche Gets Approval for Vabysmo PFS in EU for Three Retinal Diseases
12/13/24 Regeneron Down 15.5% Year to Date: How to Play the Stock?
12/13/24 Roche wins Vabysmo prefilled syringe EU approval to intensify Eylea challenge
12/12/24 Regeneron’s R&D approach scores dual wins against Alexion’s Ultomiris and in lymphoma
12/11/24 Jim Cramer Says He Would Prefer Eli Lilly (LLY) Over Regeneron Even at $900
12/11/24 Regeneron reinstated with an Underperform at BofA
12/10/24 ASH 2024: Regeneron’s Ordspono faces challenges, but positive results signal hope
12/10/24 Regeneron Pharmaceuticals (REGN): Sales Struggles and Future Prospects
12/09/24 Odronextamab ASH Presentations Underscore Impressive Potential in Earlier Lines of Treatment and Additional Types of Lymphoma
12/07/24 Novel Combination of Pozelimab and Cemdisiran (Poze-Cemdi) Achieved Greater Control of Intravascular Hemolysis in Patients with Paroxysmal Nocturnal Hemoglobinuria Compared to Ravulizumab
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
STAHL NEIL EVP Research and Dev.. EVP Research and Development Feb 02 Option 399.66 30,750 12,289,545 82,769 02/06/24
Landry Robert E EVP Finance CFO EVP Finance CFO Feb 02 Option 378.98 400 151,592 23,974 02/06/24
McCourt Marion EVP Commercial EVP Commercial Feb 05 Sell 934.71 1,000 934,710 13,789 02/06/24
Bassler Bonnie L Director Director Jan 30 Sell 959 827 793,093 1,382 01/31/24
Bassler Bonnie L Director Director Jan 30 Option 380.95 827 315,046 2,209 01/31/24
Landry Robert E EVP Finance CFO EVP Finance CFO Jan 12 Option 378.98 800 303,184 23,406 01/17/24
RYAN ARTHUR F Director Director Nov 07 Sell 828.9 100 82,890 18,547 11/08/23
Bassler Bonnie L Director Director Aug 10 Sell 789 853 673,017 1,247 08/11/23
Bassler Bonnie L Director Director Aug 10 Option 391.92 853 334,308 2,100 08/11/23
McCourt Marion EVP Commercial EVP Commercial Aug 01 Sell 744.66 250 186,165 20,053 08/03/23
VAGELOS P ROY Director Director Feb 22 Option 270.43 42,500 11,493,275 366,583 02/24/23
Landry Robert E EVP Finance CFO EVP Finance CFO Oct 31 Sell 757.9 482 365,308 28,744 11/02/22
Landry Robert E EVP Finance CFO EVP Finance CFO Oct 31 Option 381.92 2,000 763,840 30,744 11/02/22
McCourt Marion EVP Commercial EVP Commercial Nov 01 Option 372.46 1,100 409,706 20,744 11/02/22
McCourt Marion EVP Commercial EVP Commercial Nov 01 Sell 750 1,100 825,000 19,644 11/02/22
Tessier-Lavigne Marc Director Director Sep 29 Option 413.33 10,838 4,479,671 5,881 10/03/22
Tessier-Lavigne Marc Director Director Sep 29 Sell 696.44 10,838 7,548,017 2,269 10/03/22
Bassler Bonnie L Director Director Sep 08 Option 386.84 3,167 1,225,122 1,691 09/12/22
Bassler Bonnie L Director Director Sep 08 Sell 711 3,167 2,251,737 1,082 09/12/22
LAROSA JOSEPH J EVP General Counsel.. EVP General Counsel and Secret Sep 09 Option 270.43 30,000 8,112,900 41,580 09/12/22
RYAN ARTHUR F Director Director Aug 04 Option 412.58 10,453 4,312,699 21,092 08/08/22
RYAN ARTHUR F Director Director Aug 04 Sell 621.48 10,453 6,496,330 19,682 08/08/22
STAHL NEIL EVP Research and Dev.. EVP Research and Development Aug 04 Option 270.43 95,000 25,690,850 147,795 08/08/22
STAHL NEIL EVP Research and Dev.. EVP Research and Development Aug 04 Sell 613.95 23,782 14,600,959 52,795 08/08/22
RYAN ARTHUR F Director Director May 02 Sell 650.58 100 65,058 22,182 05/03/22
McCourt Marion EVP Commercial EVP Commercial May 02 Option 342.93 1,100 377,223 20,744 05/03/22
McCourt Marion EVP Commercial EVP Commercial May 02 Sell 656.97 1,100 722,667 19,644 05/03/22
Landry Robert E EVP Finance CFO EVP Finance CFO Apr 07 Option 393.75 9,500 3,740,625 32,158 04/11/22
Landry Robert E EVP Finance CFO EVP Finance CFO Apr 07 Sell 735.54 2,187 1,608,626 28,744 04/11/22
LAROSA JOSEPH J EVP General Counsel.. EVP General Counsel and Secret Apr 07 Sell 721.1 5,114 3,687,705 16,900 04/11/22
Fenimore Christopher R. SVP Controller SVP Controller Apr 08 Option 413.05 7,450 3,077,222 30,066 04/11/22
Bassler Bonnie L Director Director Apr 07 Option 380.95 1,240 472,378 2,322 04/11/22
Bassler Bonnie L Director Director Apr 07 Sell 725 1,240 899,000 1,082 04/11/22
Landry Robert E EVP Finance CFO EVP Finance CFO Mar 28 Option 462.06 14,500 6,699,870 34,212 03/30/22
Landry Robert E EVP Finance CFO EVP Finance CFO Mar 28 Sell 688.04 2,683 1,846,011 28,744 03/30/22
Van Plew Daniel P EVP & General Mgr, I.. EVP & General Mgr, Industrial Feb 22 Option 399.66 40,000 15,986,400 70,578 02/24/22
Van Plew Daniel P EVP & General Mgr, I.. EVP & General Mgr, Industrial Feb 22 Sell 612.92 6,781 4,156,211 30,578 02/24/22
BROWN MICHAEL S Director Director Feb 23 Sell 608.68 500 304,340 7,162 02/24/22
MURPHY ANDREW J EVP Research EVP Research Feb 14 Option 179.13 10,000 1,791,300 68,470 02/16/22
MURPHY ANDREW J EVP Research EVP Research Feb 14 Sell 629.34 3,540 2,227,864 58,470 02/16/22
MURPHY ANDREW J EVP Research EVP Research Dec 08 Option 52.03 16,500 858,495 75,667 12/10/21
MURPHY ANDREW J EVP Research EVP Research Dec 08 Sell 664.97 7,122 4,735,916 59,167 12/10/21
Tessier-Lavigne Marc Director Director Dec 09 Option 371.4 3,784 1,405,378 5,862 12/10/21
Tessier-Lavigne Marc Director Director Dec 09 Sell 665 3,784 2,516,360 2,078 12/10/21
Landry Robert E EVP Finance CFO EVP Finance CFO Dec 08 Option 399.66 4,250 1,698,555 34,207 12/10/21
Landry Robert E EVP Finance CFO EVP Finance CFO Dec 08 Sell 664.66 781 519,099 29,957 12/10/21
LAROSA JOSEPH J EVP General Counsel.. EVP General Counsel and Secret Dec 08 Option 179.13 30,000 5,373,900 46,520 12/10/21
SCHLEIFER LEONARD S President & CEO President & CEO Nov 19 Option 224.78 520,313 116,955,956 651,568 11/19/21
BROWN MICHAEL S Director Director Jan 27 Option 380.95 2,480 944,756 3,371 01/27/21
BROWN MICHAEL S Director Director Jan 27 Sell 554.32 2,480 1,374,714 891 01/27/21